Creegan & Nassoura Financial Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $2M | Sell |
80,301
-465
| -0.6% | -$11.7K | 1.3% | 32 |
|
|
2025
Q3 | $2.06M | Sell |
80,766
-8,515
| -10% | -$210K | 1.33% | 31 |
|
|
2025
Q2 | $2.16M | Sell |
89,281
-115
| -0.1% | -$2.68K | 1.41% | 30 |
|
|
2025
Q1 | $2.27M | Hold |
89,396
| – | – | 1.51% | 27 |
|
|
2024
Q4 | $2.37M | Sell |
89,396
-925
| -1% | -$25.1K | 1.59% | 25 |
|
|
2024
Q3 | $2.61M | Sell |
90,321
-750
| -0.8% | -$21.9K | 1.65% | 26 |
|
|
2024
Q2 | $2.55M | Hold |
91,071
| – | – | 1.75% | 19 |
|
|
2024
Q1 | $2.53M | Buy |
91,071
+27,065
| +42% | +$751K | 1.69% | 24 |
|
|
2023
Q4 | $1.84M | Buy |
64,006
+2,290
| +4% | +$69.2K | 1.34% | 32 |
|
|
2023
Q3 | $2.05M | Buy |
61,716
+900
| +1% | +$31.8K | 1.59% | 24 |
|
|
2023
Q2 | $2.23M | Buy |
60,816
+24,510
| +68% | +$954K | 1.65% | 25 |
|
|
2023
Q1 | $1.48M | Hold |
36,306
| – | – | 1.14% | 37 |
|
|
2022
Q4 | $1.86M | Sell |
36,306
-110
| -0.3% | -$5.27K | 1.45% | 32 |
|
|
2022
Q3 | $1.59M | Buy |
36,416
+100
| +0.3% | +$4.86K | 1.38% | 32 |
|
|
2022
Q2 | $1.9M | Hold |
36,316
| – | – | 1.6% | 30 |
|
|
2022
Q1 | $1.88M | Sell |
36,316
-325
| -0.9% | -$16.9K | 1.41% | 31 |
|
|
2021
Q4 | $2.16M | Hold |
36,641
| – | – | 1.64% | 23 |
|
|
2021
Q3 | $1.58M | Sell |
36,641
-325
| -0.9% | -$14.4K | 1.34% | 32 |
|
|
2021
Q2 | $1.45M | Sell |
36,966
-550
| -1% | -$21.4K | 1.24% | 36 |
|
|
2021
Q1 | $1.36M | Sell |
37,516
-50
| -0.1% | -$1.77K | 1.21% | 38 |
|
|
2020
Q4 | $1.38M | Sell |
37,566
-2,029
| -5% | -$74.4K | 1.33% | 34 |
|
|
2020
Q3 | $1.38M | Hold |
39,595
| – | – | 1.49% | 31 |
|
|
2020
Q2 | $1.23M | Sell |
39,595
-579
| -1% | -$19.7K | 1.38% | 32 |
|
|
2020
Q1 | $1.24M | Hold |
40,174
| – | – | 1.62% | 29 |
|
|
2019
Q4 | $1.49M | Buy |
+40,174
| New | +$1.43M | 1.5% | 30 |
|
|
2016
Q3 | $498K | Hold |
15,494
| – | – | 0.58% | 55 |
|
|
2016
Q2 | $518K | Sell |
15,494
-527
| -3% | -$16.8K | 0.61% | 54 |
|
|
2016
Q1 | $451K | Sell |
16,021
-900
| -5% | -$25.7K | 0.53% | 57 |
|
|
2015
Q4 | $518K | Hold |
16,921
| – | – | 0.59% | 58 |
|
|
2015
Q3 | $504K | Sell |
16,921
-253
| -1% | -$8.11K | 0.57% | 58 |
|
|
2015
Q2 | $546K | Sell |
17,174
-158
| -0.9% | -$5.15K | 0.57% | 56 |
|
|
2015
Q1 | $572K | Sell |
17,332
-580
| -3% | -$18.4K | 0.59% | 55 |
|
|
2014
Q4 | $529K | Buy |
+17,912
| New | +$514K | 0.54% | 57 |
|
Other funds holding PFE
Creegan & Nassoura Financial Group's PFE Position: Q4 2025 in Review
Creegan & Nassoura Financial Group reduced its Pfizer (PFE) stake by 0.58% in Q4 2025, selling an estimated $11.7K and leaving 80,301 shares worth $2M. The position accounts for 1.3% of the portfolio, ranked #32.
Creegan & Nassoura Financial Group first reported a position in PFE in Q4 2014 and has held it in 33 quarters since. The position peaked at $2.61M in Q3 2024. 2,906 funds tracked by Wall St. Rank hold PFE as of Q4 2025.
- Creegan & Nassoura Financial Group held 80,301 shares of Pfizer worth $2M as of Q4 2025.
- Creegan & Nassoura Financial Group sold 465 Pfizer shares in Q4 2025, an estimated $11.7K.
- Pfizer made up 1.3% of Creegan & Nassoura Financial Group's portfolio in Q4 2025, its #32 holding.
- Creegan & Nassoura Financial Group first reported a position in Pfizer in Q4 2014 and has held it in 33 quarters since.
- Creegan & Nassoura Financial Group's Pfizer position peaked at $2.61M in Q3 2024.
- 2,906 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.
Based on Creegan & Nassoura Financial Group's 13F filing for Q4 2025, filed 17 Feb 2026.